Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function.
about
Low-dose rate brachytherapy for men with localized prostate cancerThe current trend of administering a patient-generated index in the oncological setting: a systematic reviewMolecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancerAssessing quality of life in patients with prostate cancer: a systematic and standardized comparison of available instruments.Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer.Quality-of-life effects of prostate-specific antigen screening.Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials.Achieving optimal delivery of follow-up care for prostate cancer survivors: improving patient outcomesLong-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study.Proton Therapy: Ever Shifting Sands and the Opportunities and Obligations within.Transitions in Symptom Cluster Subgroups Among Men Undergoing Prostate Cancer Radiation Therapy.Impact of diagnosis and treatment of clinically localized prostate cancer on health-related quality of life for older Americans: a population-based study.Economic evaluation of treatments for patients with localized prostate cancer in Europe: a systematic review.Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer.Trajectories and predictors of symptom occurrence, severity, and distress in prostate cancer patients undergoing radiation therapyPatterns and predictors of amelioration of genitourinary toxicity after high-dose intensity-modulated radiation therapy for localized prostate cancer: implications for defining postradiotherapy urinary toxicity.Oncology Section EDGE Task Force on Prostate Cancer: A Systematic Review of Outcome Measures for Health-Related Quality of LifeThe Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples.Can erectile function be predicted after prostate cancer treatment?Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer.Prediction of erectile function following treatment for prostate cancer.Quality of life three years after diagnosis of localised prostate cancer: population based cohort study.Should we screen for and treat lower urinary tract dysfunction after major pelvic surgery? ICI-RS 2011.Potency preservation following stereotactic body radiation therapy for prostate cancer.The strategies to control prostate cancer by chemoprevention approaches.Concept and viability of androgen annihilation for advanced prostate cancer.Failure to address potential bias in non-randomised controlled clinical trials may cause lack of evidence on patient-reported outcomes: a method studyProgress and controversies: Radiation therapy for prostate cancer.Development testing of mobile health interventions for cancer patient self-management: A review.An update on sexual function and dysfunction in women.Erectile Function after Stereotactic Body Radiotherapy for Localized Prostate Cancer.Long-term quality of life after definitive treatment for prostate cancer: patient-reported outcomes in the second posttreatment decade.Silibinin prevents prostate cancer cell-mediated differentiation of naïve fibroblasts into cancer-associated fibroblast phenotype by targeting TGF β2.Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment.Long-term health care costs for patients with prostate cancer: a population-wide longitudinal study in New South Wales, Australia.Comparison of distribution- and anchor-based approaches to infer changes in health-related quality of life of prostate cancer survivors.Assessment of acute bowel function after radiotherapy for prostate cancer: Is it accurate enough?Patient-reported outcomes in cancer survivorship.Factors associated with current and severe physical side-effects after prostate cancer treatment: What men report.Dose-Escalated Stereotactic Body Radiation Therapy for Prostate Cancer: Quality-of-Life Comparison of Two Prospective Trials.
P2860
Q24235544-F304F3D9-21A7-474E-B0C6-DEE441651C64Q26823678-8B585C1E-4D28-4389-BDB8-DB081B9E0669Q26995304-7F7B843F-CAF2-444F-8E21-818788BEFF6BQ34136485-98F41BBD-ACF3-4EA5-8F82-DE123A3419E3Q34268907-E666A83C-FB5E-48B5-B280-BFA14AB0D6B4Q34294102-D06A0261-52E8-4EFE-9C54-0916FBA45A89Q34315605-01BAFCF2-4CF0-4126-A108-0020DE7979CAQ35212795-6BD91E02-6146-4042-B56C-BBAFF50BFF87Q35654258-2AC57FED-F6EA-4512-B7E7-7C92C49198BDQ35971106-B69431D7-5DEB-4D64-87EA-154D70C069A3Q36001854-FFEFDEE6-58BE-4060-99F0-1698B778F778Q36133773-4D7CACF9-BC12-4179-A6CD-4821C13842A3Q36157299-FD990F63-260F-49CE-B8AA-72194E10139BQ36174829-02056A05-B72E-407E-BA66-77E8D8FE9C90Q36296032-843982C5-F10A-491A-A9A6-66C900BEF1F9Q36672787-8C4E872A-A28E-4F9D-8C7D-9D78219D5B64Q36852329-88E7EDDD-47D5-4C18-84F5-B45507C11105Q37028549-1FB36F7C-6673-46E0-96C2-0DB1E2A8884EQ37074583-177CF7DB-4D15-4129-AFD7-11298F086A91Q37253842-2AE22650-783E-4A26-8DF7-8E68336233F7Q37318611-F2A7BEFB-7789-4722-BE54-A1D5CBF7E9D0Q37444820-2FE8117E-ACA7-454A-9C6F-0977A679AA14Q37993499-0AAD7A6D-1326-445A-846F-66D753C2C9DCQ38158080-950442D1-51F2-460D-9EE4-0165BF9E5145Q38175776-88744A8B-4BBD-4C46-857F-C2D5D821DA7BQ38207556-D027A40A-BA0A-4810-8193-21025BC240E7Q38217667-B2A591EE-036E-438A-B3D8-025E480443D9Q38252429-A2462464-8185-4CCB-8AE5-640F99F2606DQ38444724-A31C8250-1FE2-44B5-A2C3-A1A4510704B0Q38454048-43FC3D0C-0756-4195-BCA1-8027CFE50FEEQ38677828-46AF40F7-061A-4916-890C-A41D9BAE7812Q38754823-2860DB54-BD1D-4CFF-926D-1DEFB9AD41D9Q39016642-0C8A00FD-70C8-414A-9350-54FD837B9F6FQ39167790-7A97982F-7898-4A4D-90A5-BAF064ABFFF5Q39399525-F6700DF7-0F3A-4520-9F77-5663BF060CA6Q40026261-B556EE76-F791-4AAD-A141-5EB4DDA6BF09Q40044229-ADE0D929-D25C-4558-9E06-A717750DCD67Q40382166-293A6A93-F806-4FFE-AF60-A6737F17B9A1Q40547127-0D9F96B5-24DF-432D-9AAC-178E48C59578Q40965160-F6C9455B-0275-40A5-B998-2589DAB6EABA
P2860
Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Individualizing quality-of-lif ...... y, bowel, and sexual function.
@en
Individualizing quality-of-lif ...... y, bowel, and sexual function.
@nl
type
label
Individualizing quality-of-lif ...... y, bowel, and sexual function.
@en
Individualizing quality-of-lif ...... y, bowel, and sexual function.
@nl
prefLabel
Individualizing quality-of-lif ...... y, bowel, and sexual function.
@en
Individualizing quality-of-lif ...... y, bowel, and sexual function.
@nl
P356
P1476
Individualizing quality-of-lif ...... y, bowel, and sexual function.
@en
P2093
James A Talcott
Ronald C Chen
P304
P356
10.1200/JCO.2008.18.6486
P407
P50
P577
2009-07-20T00:00:00Z